Compare HSIC & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HSIC | GKOS |
|---|---|---|
| Founded | 1932 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 8.7B |
| IPO Year | 1996 | 2015 |
| Metric | HSIC | GKOS |
|---|---|---|
| Price | $85.84 | $153.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 12 |
| Target Price | $85.07 | ★ $126.92 |
| AVG Volume (30 Days) | ★ 1.1M | 768.7K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.21 | N/A |
| EPS | ★ 0.92 | N/A |
| Revenue | ★ $13,201,995,000.00 | $507,442,000.00 |
| Revenue This Year | $6.12 | $23.32 |
| Revenue Next Year | $3.64 | $27.43 |
| P/E Ratio | $93.70 | ★ N/A |
| Revenue Growth | 5.94 | ★ 32.33 |
| 52 Week Low | $61.97 | $73.16 |
| 52 Week High | $89.34 | $161.53 |
| Indicator | HSIC | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 59.13 | 61.84 |
| Support Level | $70.52 | $96.44 |
| Resistance Level | $88.51 | N/A |
| Average True Range (ATR) | 1.91 | 6.25 |
| MACD | -0.16 | -0.15 |
| Stochastic Oscillator | 53.83 | 65.68 |
Henry Schein Inc is a solutions company for healthcare professionals. It offers healthcare equipment, products, and services to office-based dental and medical practitioners, as well as alternative sites of care. The company's reportable segments are: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology. It generates maximum revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services. This segment also includes value-added services such as financial services, continuing education services, consulting, and other practice services.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.